The Vial Fill-Finish Process, End to End: Where the Closure System Fits

Vial fill-finish is the final manufacturing stage for an injectable drug: the sequence that turns a formulated bulk solution and a set of cleaned, sterilised packaging components into sealed, inspected, labelled vials ready for release. It runs as two parallel streams that meet at the filling machine, a product stream and a component stream, followed by filling, stoppering, optional freeze-drying, capping, inspection, integrity testing, labelling and release. Sealing is one stage inside that chain, not the whole of it, and it only works if everything upstream has already gone right.

This guide walks the chain end to end, shows where the container closure system enters it, and explains what has to line up for the closure to integrate cleanly with the line.

Key takeaways

Fill-finish is the stage between bulk drug substance and a finished, sealed vial. It is where most of the sterility risk in an injectable product sits.
The line has two input streams: the sterile-filtered product, and the washed, depyrogenated or sterilised components (vial, stopper, seal).
Glass vials are typically washed then dry-heat depyrogenated, with a validated cycle demonstrating at least a 3 log reduction in endotoxin, commonly at 250 °C and above.
Capping completes the container closure system. Before it, the stopper only rests in the vial mouth; after it, the package is closed.
Under EU GMP Annex 1, vials with missing or displaced stoppers are rejected before capping, and stoppered vials are protected by a Grade A air supply until the cap is crimped when capping runs outside the aseptic core.
Every filled unit is 100% visually inspected, and package integrity is demonstrated separately by container closure integrity testing.
Closure integration is mostly a dimensional and cleanliness problem: the vial, stopper and seal have to match each other and feed reliably at line speed.

What fill-finish means

Fill-finish covers everything from the point a formulated, filterable bulk exists to the point sealed vials are released for packing. Upstream of it sits drug substance manufacture and formulation; downstream sits distribution. Fill-finish is where the product first meets its final container, which is why regulators treat it as the highest-risk stage of a sterile product’s manufacture.

Two production models exist. In terminal sterilisation, the product is filled and sealed and the closed unit is then sterilised, usually by moist heat. In aseptic processing, the product and every component are sterilised separately and brought together in a controlled environment, because the formulation cannot survive a terminal cycle. Most biologics, most vaccines and most lyophilised products use aseptic processing, and it is the harder case, since sterility depends on the process rather than on a final kill step. The FDA’s guidance on sterile drug products produced by aseptic processing (September 2004) and EU GMP Annex 1 set the expectations.

The component stream: preparing the vial, stopper and seal

Before anything is filled, the primary packaging has to arrive clean and be rendered free of viable organisms and, for the glass, of endotoxin. The three components take three different routes.

Glass vials are washed with purified and water-for-injection rinses, then passed through a dry heat tunnel. The tunnel both sterilises and depyrogenates: USP <1228.1> covers dry heat depyrogenation, and a cycle is validated by showing at least a 3 log (1000 fold) reduction of a bacterial endotoxin challenge, typically at 250 °C or higher for a defined dwell. Vials exit the tunnel into the filling zone, so the tunnel is also the physical boundary into the aseptic core.
Rubber stoppers are washed, siliconised where the design calls for it, and sterilised by moist heat, or bought ready-to-sterilise or ready-to-use in sterile bags. They must also be dried, because residual moisture affects both filling and lyophilisation.
Aluminium and aluminium-plastic seals are supplied clean and are handled according to where capping happens. If capping is performed inside the aseptic core, the seals are sterilised and transferred in aseptically. If capping is performed as a clean process outside the core, which is common, the seals are used in a controlled but non-sterile state under a Grade A air supply. Either way the incoming cleanliness of the seal matters, since it is the last component to touch the closed vial.

Component preparation is not a side activity. It is a parallel production line with its own validated cycles, its own hold times, and its own records, and a delay in it stops the filling line.

The product stream: formulation to sterile filtration

On the product side, the bulk is compounded, controlled for bioburden, and sterile-filtered on its way to the filling needles. Compounding dissolves or dilutes the drug substance with excipients to the target concentration, with in-process checks on pH, appearance and assay. Bioburden is measured on the pre-filtration bulk, because a sterilising filter is validated against a defined challenge rather than an unlimited one.

Sterile filtration then passes the bulk through a sterilising-grade filter, conventionally rated at 0.22 µm or finer, into a sterile holding vessel or straight to the filling manifold. Filter integrity is tested before and after use, and a post-use failure invalidates the batch behind it. For products that cannot be filtered, the sterility assurance strategy changes entirely, but for the large majority of vialled injectables this is the step that makes the product sterile.

Filling, stoppering and freeze-drying

Filling doses the product into each vial; stoppering seats the elastomeric closure that will form the sterile barrier. Filling is by peristaltic, rotary piston, time-pressure or mass-flow systems depending on volume and shear sensitivity, with in-process fill weight checks at set intervals and, on many lines, 100% check-weighing. The open vial is exposed only inside the highest-grade zone, under unidirectional airflow, in an isolator or a restricted access barrier system.

Stoppering follows immediately. The stopper is placed and pressed into the vial mouth so its sealing surfaces contact the glass. At this point the vial is closed but not sealed: the stopper is held only by friction and can be displaced.

For a lyophilised product the sequence branches. Slotted freeze-drying stoppers are seated in a raised position so water vapour can escape, the loaded vials go into the freeze-dryer, and at the end of the cycle the dryer shelves press every stopper fully home, often under vacuum or an inert gas, before the chamber is opened. Only then do the vials go to capping.

Capping: completing the container closure system

Capping is the step that turns a stoppered vial into a sealed package, by crimping an aluminium or aluminium-plastic seal over the stopper and under the vial neck flange. Until this happens the stopper can lift, so capping is where the container closure system actually becomes a system.

Annex 1 places specific expectations here. Vials with a missing or displaced stopper are detected and rejected before capping, not after, because a raised stopper that gets crimped over looks acceptable and is not. Where capping is carried out as a clean process outside the aseptic core, stoppered vials are protected by a Grade A air supply until the cap is crimped. The mechanics of the crimp itself are covered in vial crimping explained, the sterility controls around it in sterile vial sealing, and the equipment that carries it out, from bench-top crimpers to inline rotary cappers, in vial sealing machine types. The architecture of the machine at this station, how the seals are sorted and fed, how crimp force is servo-controlled per cycle, and what the reject logic looks at, is set out in automated vial capping systems.

After capping: inspection, integrity and release

Once sealed, every unit is inspected, the package is shown to be integral, and the batch is documented and released. The steps run in this order:

External decontamination or washing. Sealed vials may be washed or wiped to remove residue before they leave the classified area.
100% visual inspection. Every filled unit is examined for visible particulates, fill volume, glass defects, and closure defects such as a missing, raised, loose or damaged seal. Manual, semi-automated and fully automated vision systems are all used; the expectations sit in USP <790> and the accompanying informational chapter on visual inspection. Sub-visible particulate limits are set separately, under USP <788>.
Container closure integrity testing. Integrity is demonstrated by a leak test method chosen and validated within the framework of USP <1207>, applied at development, on stability, and per the control strategy in routine production.
Labelling and secondary packaging, with reconciliation of labels issued against units labelled.
Batch review and release, including the batch record, environmental monitoring results, the aseptic process simulation history for that line, and sterility and endotoxin testing as required.

How the closure system integrates with the line

Closure integration is a dimensional and behavioural problem: the vial, stopper and seal have to fit each other, and the seal has to feed and crimp identically thousands of times an hour. Three things carry most of the risk.

The dimension chain. Vial neck finish, seated stopper height, and seal skirt length stack up. The ISO 8362 series exists to keep that stack compatible: ISO 8362-1 for tubing vials, Part 2 for closures, Part 3 for plain aluminium caps, and Parts 6 and 7 for aluminium-plastics combination caps. If one component is sourced against a different drawing, the crimp window moves.
Piece-to-piece consistency. A capping head is set once for a lot. Variation in seal diameter, skirt height or metal gauge shows up as variation in the finished crimp and, past a point, as rejects. This is the same argument made in how seal design affects capping throughput.
Cleanliness of the incoming component. Loose particles or coating debris on a seal end up on the outside of a sterile vial and, in the worst case, inside the crimp interface.

Because of that stack-up, the vial, stopper and seal are qualified together for a product rather than individually, and a change to any one of them is assessed against the other two.

How this works in practice at Autofits

Autofits sits on the component stream of the chain described above, supplying the seals that the capping station crimps at the end of it: FlipTop aluminium-plastic seals, tear-off and tear-down aluminium seals, and aluminium pilfer-proof (ROPP) caps across the product range. Because the seal arrives at the last controlled step before a vial is closed, it is produced to tight dimensional tolerances and screened by high-speed visual inspection, so it feeds and crimps predictably on a customer’s line. Production runs in a 75,000 sq ft Nashik facility with an ISO Class 8 cleanroom, under an ISO 15378:2017 quality system alongside ISO 9001:2015 and ISO 14001:2015 certification and a Drug Master File.

Frequently asked questions

What is the vial fill-finish process?

Vial fill-finish is the final manufacturing stage for an injectable drug, covering everything from a formulated bulk solution to sealed, inspected vials ready for release. It combines a product stream (compounding, bioburden control, sterile filtration) with a component stream (vial washing and depyrogenation, stopper preparation, seal supply), then fills, stoppers, freeze-dries where required, caps, inspects, integrity-tests, labels and releases.

What are the stages of a fill-finish line in order?

Component preparation and sterile filtration run in parallel, then the line runs: filling, stoppering, lyophilisation if the product is freeze-dried, capping, external decontamination, 100% visual inspection, container closure integrity testing, labelling and secondary packaging, and batch review and release.

Where does sealing fit into fill-finish?

Sealing, or capping, sits after filling and stoppering and after lyophilisation where that applies. It is the step that completes the container closure system by crimping an aluminium or aluminium-plastic seal over the stopper. Everything after it, inspection, integrity testing and labelling, verifies and finishes a package that is already closed.

Why are vials depyrogenated before filling?

Because sterilisation kills organisms but does not destroy the bacterial endotoxin they leave behind, and endotoxin in an injectable causes a pyrogenic reaction. Glass vials are therefore passed through a dry heat tunnel after washing, on a cycle validated to reduce a bacterial endotoxin challenge by at least 3 log, commonly at 250 °C or above. USP <1228.1> covers dry heat depyrogenation.

What does EU GMP Annex 1 require at the capping step?

Annex 1 treats capping as a critical step. Vials with missing or displaced stoppers are to be detected and rejected before capping rather than after, and where capping is performed as a clean process outside the aseptic core, stoppered vials are protected with a Grade A air supply until the cap has been crimped. Capped vials are then inspected for defects.

What has to match between the vial, stopper and seal?

The vial neck finish, the seated height of the stopper, and the seal’s diameter and skirt length form a dimension chain that has to close within the capping head’s window. The ISO 8362 series dimensions these components to be compatible with each other. Because the tolerances stack, the three are qualified together for a product and a change to one is assessed against the other two.

Sources

European Commission: EudraLex Volume 4, EU GMP Annex 1, Manufacture of Sterile Medicinal Products (2022) (https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en)
FDA: Guidance for Industry, Sterile Drug Products Produced by Aseptic Processing, Current Good Manufacturing Practice, September 2004 (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sterile-drug-products-produced-aseptic-processing-current-good-manufacturing-practice)
USP-NF: General Chapter <1228.1>, Dry Heat Depyrogenation (https://www.usp.org/)
USP-NF: General Chapter <790>, Visible Particulates in Injections (https://www.usp.org/)
USP-NF: General Chapter <1207>, Package Integrity Evaluation, Sterile Products (https://www.usp.org/)
ISO: ISO 8362-1:2018, Injection containers and accessories, Part 1: Injection vials made of glass tubing (https://www.iso.org/standard/74398.html)

*Last updated: 2026-07-31. This article is general technical information, not regulatory or compliance advice; confirm current standard editions and requirements with the issuing bodies.*